Experimental studies on the production of pulmonary infarction. IV. Effects of UK, heparin, t-AMCHA or ellagic acid.
D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006490:Hemostatics / Q000494:pharmacology / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007238:Infarction / Q000517:prevention & control*; D008168:Lung / Q000098:blood supply*; D008744:Methylamines / Q000494:pharmacology / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000097:blood; D011817:Rabbits; D013927:Thrombosis / Q000517:prevention & control
D000933:Antifibrinolytic Agents; D001578:Benzopyrans; D003509:Cyclohexanecarboxylic Acids; D005343:Fibrinolytic Agents; D006490:Hemostatics; D008744:Methylamines; D006493:Heparin